Abstract:Background: Plasma proteins, directly secreted from tumor cells or a result of the body's response to a tumor, may have utility for early detection. We aimed to identify plasma protein combinations that predict prediagnostic cancers in a prospective study. Methods: We sampled from 8,186 ARIC study participants without a cancer diagnosis at blood draw and with 4,877 log2-transformed proteins measured by SomaScan. We selected as cases those diagnosed within 5 years after blood draw and were registry/medical record confirmed. We selected as controls those who never had a cancer history by 2015 and did not die of cancer. Participants with possible liver, kidney, or inflammatory conditions were excluded (eGFR-cr ±0.75), abundant or known markers (albumin, CRP, PSA), and proteins with wide log2-transformed distributions (SD>1 and >10% outliers-1.5 IQR away from 25th or 75th percentile) among controls were excluded. Recursive feature elimination (RFE) with random forest (RF) was used to select the top 10 informative proteins based on accuracy. Non-protein features included demographic, lifestyle (e.g., smoking), and medical factors. We next divided participants into train and test sets in 7:3 ratio stratified by case status. RF including top 10 proteins from the RFE and non-protein features trained in the train set were used to predict near-term cancer status in the test set and to calculate prediction performance. Random Over-Sampling Examples were used to balance between rare cases (<3%) and controls in the dataset. Results: We included 210 cases (98 diagnosed within 2 years) and 7,042 controls with 3,476 proteins. 58% were female, 24% were Black, and median age was 57 years (IQR: 52-62). The most common cancer was lung (27%). In the test set, sensitivity and specificity of the model for total cases diagnosed within 2 years were 0.19 and 0.91. Results for cases diagnosed within 3 (0.24, 0.88) and 5 (0.29, 0.87) years were similar. Using the top 10 informative proteins for total cancer, sensitivity was 0.68 and specificity was 0.56 for lung cancers diagnosed within 2 years; for lung cancers diagnosed within 3 (0.55, 0.77) or 5 (0.53, 0.79) years, sensitivity decreased but specificity increased. Using the top 10 informative proteins specific for lung cancer, which did not overlap with the top 10 for total cancer, sensitivity and specificity were 0.69 and 0.67 for lung cancers diagnosed within 2 years. Conclusions: In this study, in which blood draw preceded diagnosis, top informative proteins did not provide sufficient sensitivity for all-cancer near-term prediction. For lung cancer, further optimization may improve the sensitivity and specificity to achieve the range required for population implementation for screening. Validation with more cases, and on other proteomic platforms are needed. Funding NHLBI, NCI, NPCR Citation Format: Meng Ru, Christopher Douville, Kenneth R. Butler, Corinne E. Joshu, Jiayun Lu, Anna Prizment, Josef Coresh, Elizabeth A. Platz. Identification of plasma proteins for early detection of cancer, including lung, in the Atherosclerosis Risk in Communities (ARIC) study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6084.

Evaluation of circulating plasma proteins in breast cancer using Mendelian randomisation

Identifying new biomarkers and potential therapeutic targets for breast cancer through the integration of human plasma proteomics: a Mendelian randomization study and colocalization analysis

Identifying therapeutic targets for cancer among 2074 circulating proteins and risk of nine cancers

Evaluation of circulating plasma proteins in prostate cancer using mendelian randomization

Elucidating the susceptibility to breast cancer: an in-depth proteomic and transcriptomic investigation into novel potential plasma protein biomarkers

Identifying proteomic risk factors for overall, aggressive, and early onset prostate cancer using Mendelian Randomisation and tumour spatial transcriptomics

Identifying proteomic risk factors for overall, aggressive and early onset prostate cancer using Mendelian randomization and tumor spatial transcriptomics

Identification of novel protein biomarkers and drug targets for colorectal cancer by integrating human plasma proteome with genome

Circulating Micrornas As Specific Biomarkers for Breast Cancer Detection

Exploration of potential novel drug targets and biomarkers for small cell lung cancer by plasma proteome screening

Identification of circulating metabolites linked to the risk of breast cancer: a mendelian randomization study

Identifying proteomic risk factors for cancer using prospective and exome analyses: 1,463 circulating proteins and risk of 19 cancers in the UK Biobank

Integrative Analysis of Plasma Metabolomics and Proteomics Reveals the Metabolic Landscape of Breast Cancer

Identifying therapeutic targets for breast cancer: insights from systematic Mendelian randomization analysis

Plasma proteometabolome in lung cancer: exploring biomarkers through bidirectional Mendelian randomization and colocalization analysis

Causal associations between plasma proteins and prostate cancer: a Proteome-Wide Mendelian Randomization

Abstract 6084: Identification of plasma proteins for early detection of cancer, including lung, in the Atherosclerosis Risk in Communities (ARIC) study

A two-step strategy for identification of plasma protein biomarkers for endometrial and ovarian cancer

Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study

Abstract 784: Proteome-wide mendelian randomization identifies causal association between plasma proteins and lung cancer

Detection of endometrial cancer in cervico-vaginal fluid and blood plasma: leveraging proteomics and machine learning for biomarker discovery